Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats [Retraction]
Zulfiqar Z, Shah FA, Shafique S, et al. J Inflamm Res. 2020;13:1185–1205. The Editor and Publisher of Journal of Inflammation Research wish to retract the published article. Concerns were raised regarding the duplication of several images from Figures 9–11. Specifically, Figure 9...
Saved in:
Main Authors: | Zulfiqar Z (Author), Shah FA (Author), Shafique S (Author), Alattar A (Author), Ali T (Author), Alvi AM (Author), Rashid S (Author), Li S (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats
by: Zulfiqar Z, et al.
Published: (2020) -
Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
by: Nader S. Abutaleb, et al.
Published: (2022) -
A Potent Antioxidant Endogenous Neurohormone Melatonin, Rescued MCAO by Attenuating Oxidative Stress-Associated Neuroinflammation
by: Li Ling, et al.
Published: (2020) -
1,3,4, Oxadiazole Compound A3 Provides Robust Protection Against PTZ-Induced Neuroinflammation and Oxidative Stress by Regulating Nrf2-Pathway [Retraction]
by: Alvi AM, et al.
Published: (2022) -
Polydatin Attenuates Neuronal Loss via Reducing Neuroinflammation and Oxidative Stress in Rat MCAO Models
by: Fawad Ali Shah, et al.
Published: (2019)